Bio Simulation - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509241452

Publication Date:

September 19, 2024

Pages:

133

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Biosimulation is computer-aided mathematical simulation of biological processes and systems and thus is an integral part of systems biology.
The global market for Bio Simulation was estimated to be worth US$ 1067 million in 2023 and is forecast to a readjusted size of US$ 2926.1 million by 2030 with a CAGR of 15.0% during the forecast period 2024-2030
North American market for Bio Simulation was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bio Simulation was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Bio Simulation was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Bio Simulation include Altair Engineering Inc., ANSYS Inc., Certara LP, Dassault Systemes SE, Genedata AG, Intelligen Inc., Physiomics Plc, PPD Inc. and Schrodinger Inc., etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bio Simulation, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Bio Simulation by region & country, by Type, and by Application.
The Bio Simulation market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bio Simulation.
麻豆原创 Segmentation
By Company
Altair Engineering Inc.
ANSYS Inc.
Certara LP
Dassault Systemes SE
Genedata AG
Intelligen Inc.
Physiomics Plc
PPD Inc.
Schrodinger Inc.
Simulations Plus Inc.
Rhenovia Pharma
Medtronic
Advanced Chemistry Development
Chemical Computing Group
Entelos Holding Corporation
Segment by Type:
Software
Services
Segment by Application
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Other End Users
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Bio Simulation manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Bio Simulation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Bio Simulation in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Bio Simulation Product Introduction
1.2 Global Bio Simulation 麻豆原创 Size Forecast
1.3 Bio Simulation 麻豆原创 Trends & Drivers
1.3.1 Bio Simulation Industry Trends
1.3.2 Bio Simulation 麻豆原创 Drivers & Opportunity
1.3.3 Bio Simulation 麻豆原创 Challenges
1.3.4 Bio Simulation 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Bio Simulation Players Revenue Ranking (2023)
2.2 Global Bio Simulation Revenue by Company (2019-2024)
2.3 Key Companies Bio Simulation Manufacturing Base Distribution and Headquarters
2.4 Key Companies Bio Simulation Product Offered
2.5 Key Companies Time to Begin Mass Production of Bio Simulation
2.6 Bio Simulation 麻豆原创 Competitive Analysis
2.6.1 Bio Simulation 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Bio Simulation Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bio Simulation as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Software
3.1.2 Services
3.2 Global Bio Simulation Sales Value by Type
3.2.1 Global Bio Simulation Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Bio Simulation Sales Value, by Type (2019-2030)
3.2.3 Global Bio Simulation Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmaceutical and Biotechnology Companies
4.1.2 Contract Research Organizations
4.1.3 Other End Users
4.2 Global Bio Simulation Sales Value by Application
4.2.1 Global Bio Simulation Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Bio Simulation Sales Value, by Application (2019-2030)
4.2.3 Global Bio Simulation Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Bio Simulation Sales Value by Region
5.1.1 Global Bio Simulation Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Bio Simulation Sales Value by Region (2019-2024)
5.1.3 Global Bio Simulation Sales Value by Region (2025-2030)
5.1.4 Global Bio Simulation Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Bio Simulation Sales Value, 2019-2030
5.2.2 North America Bio Simulation Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Bio Simulation Sales Value, 2019-2030
5.3.2 Europe Bio Simulation Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Bio Simulation Sales Value, 2019-2030
5.4.2 Asia Pacific Bio Simulation Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Bio Simulation Sales Value, 2019-2030
5.5.2 South America Bio Simulation Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Bio Simulation Sales Value, 2019-2030
5.6.2 Middle East & Africa Bio Simulation Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Bio Simulation Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Bio Simulation Sales Value
6.3 United States
6.3.1 United States Bio Simulation Sales Value, 2019-2030
6.3.2 United States Bio Simulation Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Bio Simulation Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Bio Simulation Sales Value, 2019-2030
6.4.2 Europe Bio Simulation Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Bio Simulation Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Bio Simulation Sales Value, 2019-2030
6.5.2 China Bio Simulation Sales Value by Type (%), 2023 VS 2030
6.5.3 China Bio Simulation Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Bio Simulation Sales Value, 2019-2030
6.6.2 Japan Bio Simulation Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Bio Simulation Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Bio Simulation Sales Value, 2019-2030
6.7.2 South Korea Bio Simulation Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Bio Simulation Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Bio Simulation Sales Value, 2019-2030
6.8.2 Southeast Asia Bio Simulation Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Bio Simulation Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Bio Simulation Sales Value, 2019-2030
6.9.2 India Bio Simulation Sales Value by Type (%), 2023 VS 2030
6.9.3 India Bio Simulation Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Altair Engineering Inc.
7.1.1 Altair Engineering Inc. Profile
7.1.2 Altair Engineering Inc. Main Business
7.1.3 Altair Engineering Inc. Bio Simulation Products, Services and Solutions
7.1.4 Altair Engineering Inc. Bio Simulation Revenue (US$ Million) & (2019-2024)
7.1.5 Altair Engineering Inc. Recent Developments
7.2 ANSYS Inc.
7.2.1 ANSYS Inc. Profile
7.2.2 ANSYS Inc. Main Business
7.2.3 ANSYS Inc. Bio Simulation Products, Services and Solutions
7.2.4 ANSYS Inc. Bio Simulation Revenue (US$ Million) & (2019-2024)
7.2.5 ANSYS Inc. Recent Developments
7.3 Certara LP
7.3.1 Certara LP Profile
7.3.2 Certara LP Main Business
7.3.3 Certara LP Bio Simulation Products, Services and Solutions
7.3.4 Certara LP Bio Simulation Revenue (US$ Million) & (2019-2024)
7.3.5 Dassault Systemes SE Recent Developments
7.4 Dassault Systemes SE
7.4.1 Dassault Systemes SE Profile
7.4.2 Dassault Systemes SE Main Business
7.4.3 Dassault Systemes SE Bio Simulation Products, Services and Solutions
7.4.4 Dassault Systemes SE Bio Simulation Revenue (US$ Million) & (2019-2024)
7.4.5 Dassault Systemes SE Recent Developments
7.5 Genedata AG
7.5.1 Genedata AG Profile
7.5.2 Genedata AG Main Business
7.5.3 Genedata AG Bio Simulation Products, Services and Solutions
7.5.4 Genedata AG Bio Simulation Revenue (US$ Million) & (2019-2024)
7.5.5 Genedata AG Recent Developments
7.6 Intelligen Inc.
7.6.1 Intelligen Inc. Profile
7.6.2 Intelligen Inc. Main Business
7.6.3 Intelligen Inc. Bio Simulation Products, Services and Solutions
7.6.4 Intelligen Inc. Bio Simulation Revenue (US$ Million) & (2019-2024)
7.6.5 Intelligen Inc. Recent Developments
7.7 Physiomics Plc
7.7.1 Physiomics Plc Profile
7.7.2 Physiomics Plc Main Business
7.7.3 Physiomics Plc Bio Simulation Products, Services and Solutions
7.7.4 Physiomics Plc Bio Simulation Revenue (US$ Million) & (2019-2024)
7.7.5 Physiomics Plc Recent Developments
7.8 PPD Inc.
7.8.1 PPD Inc. Profile
7.8.2 PPD Inc. Main Business
7.8.3 PPD Inc. Bio Simulation Products, Services and Solutions
7.8.4 PPD Inc. Bio Simulation Revenue (US$ Million) & (2019-2024)
7.8.5 PPD Inc. Recent Developments
7.9 Schrodinger Inc.
7.9.1 Schrodinger Inc. Profile
7.9.2 Schrodinger Inc. Main Business
7.9.3 Schrodinger Inc. Bio Simulation Products, Services and Solutions
7.9.4 Schrodinger Inc. Bio Simulation Revenue (US$ Million) & (2019-2024)
7.9.5 Schrodinger Inc. Recent Developments
7.10 Simulations Plus Inc.
7.10.1 Simulations Plus Inc. Profile
7.10.2 Simulations Plus Inc. Main Business
7.10.3 Simulations Plus Inc. Bio Simulation Products, Services and Solutions
7.10.4 Simulations Plus Inc. Bio Simulation Revenue (US$ Million) & (2019-2024)
7.10.5 Simulations Plus Inc. Recent Developments
7.11 Rhenovia Pharma
7.11.1 Rhenovia Pharma Profile
7.11.2 Rhenovia Pharma Main Business
7.11.3 Rhenovia Pharma Bio Simulation Products, Services and Solutions
7.11.4 Rhenovia Pharma Bio Simulation Revenue (US$ Million) & (2019-2024)
7.11.5 Rhenovia Pharma Recent Developments
7.12 Medtronic
7.12.1 Medtronic Profile
7.12.2 Medtronic Main Business
7.12.3 Medtronic Bio Simulation Products, Services and Solutions
7.12.4 Medtronic Bio Simulation Revenue (US$ Million) & (2019-2024)
7.12.5 Medtronic Recent Developments
7.13 Advanced Chemistry Development
7.13.1 Advanced Chemistry Development Profile
7.13.2 Advanced Chemistry Development Main Business
7.13.3 Advanced Chemistry Development Bio Simulation Products, Services and Solutions
7.13.4 Advanced Chemistry Development Bio Simulation Revenue (US$ Million) & (2019-2024)
7.13.5 Advanced Chemistry Development Recent Developments
7.14 Chemical Computing Group
7.14.1 Chemical Computing Group Profile
7.14.2 Chemical Computing Group Main Business
7.14.3 Chemical Computing Group Bio Simulation Products, Services and Solutions
7.14.4 Chemical Computing Group Bio Simulation Revenue (US$ Million) & (2019-2024)
7.14.5 Chemical Computing Group Recent Developments
7.15 Entelos Holding Corporation
7.15.1 Entelos Holding Corporation Profile
7.15.2 Entelos Holding Corporation Main Business
7.15.3 Entelos Holding Corporation Bio Simulation Products, Services and Solutions
7.15.4 Entelos Holding Corporation Bio Simulation Revenue (US$ Million) & (2019-2024)
7.15.5 Entelos Holding Corporation Recent Developments
8 Industry Chain Analysis
8.1 Bio Simulation Industrial Chain
8.2 Bio Simulation Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Bio Simulation Sales Model
8.5.2 Sales Channel
8.5.3 Bio Simulation Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Altair Engineering Inc.
ANSYS Inc.
Certara LP
Dassault Systemes SE
Genedata AG
Intelligen Inc.
Physiomics Plc
PPD Inc.
Schrodinger Inc.
Simulations Plus Inc.
Rhenovia Pharma
Medtronic
Advanced Chemistry Development
Chemical Computing Group
Entelos Holding Corporation

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.